Abstract:Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00763?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00763</a>.Virtual screening results from the molecular docking; compounds identified as hits against RORγ from virtual screening; overlaid complex structures of compound XY101 and compound 27h; overlaid structures of compounds 27g and 27h; western blot analysis of the AR and AR variants levels in 22Rv1 cells treated with compound 27h; metabolic stability of 25c, 25p, 27g, and 27h in human and rat liver microsomes; 1H and 13C NMR spectra of the synthesized compounds; and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_001.pdf">PDF</a>)Molecular formula strings for compounds with associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_002.csv">CSV</a>)Database files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of new chalone adamantyl arotinoids having RXRα-modulating and anticancer activities

Discovery of bipyridine amide derivatives targeting p RXRα-PLK1 interaction for anticancer therapy

Synthesis and Biological Evaluation of Amino Chalcone Derivatives as Antiproliferative Agents

The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader

Discovery of 4'-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation

Discovery of ARD-2051 As a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Discovery of N -(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2

Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents

Synthesis and biological evaluation of the novel antitumor agent 3'-monosubstituted chalcone derivatives

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents

Synthesis, Molecular Modeling and Biological Evaluation of Chalcone Thiosemicarbazide Derivatives As Novel Anticancer Agents.

A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products

Preparation of novel anthraquinone-based aspirin derivatives with anti-cancer activity

Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells

Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors

Design, Synthesis, and Apoptosis-Promoting Effect Evaluation of Rhopaladins' Analog 4-Arylidene-5-Oxopyrrolidine Derivatives

Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists

Discovery and optimization of anthraquinone derivatives containing substituted bisbenzyloxy groups as a novel scaffold damaged endoplasmic reticulum and against hepatocellular carcinoma cells